This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Gabapentin: Difference between revisions
>Azed Added an entry for the United Kingdom to the Legal Status section. |
>SkinwalkerSchizo m Added one comma after "...certain calcium channels in the brain..."; small grammatical improvement |
||
| Line 2: | Line 2: | ||
{{SummarySheet}} | {{SummarySheet}} | ||
{{SubstanceBox/Gabapentin}} | {{SubstanceBox/Gabapentin}} | ||
'''Gabapentin''' (also known as '''Neurontin''') is a [[psychoactive class::depressant]] substance of the [[chemical class::gabapentinoid]] class. It is a structural analog of the [[neurotransmitter]] [[GABA]] and acts by inhibiting certain calcium channels in the brain namely α2δ subunit-containing voltage-dependent calcium channels (VGCCs).<ref name="CalandreRico-Villademoros2016">{{cite journal|last1=Calandre|first1=Elena P.|last2=Rico-Villademoros|first2=Fernando|last3=Slim|first3=Mahmoud|title=Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use|journal=Expert Review of Neurotherapeutics|volume=16|issue=11|year=2016|pages=1263–1277|issn=1473-7175|doi=10.1080/14737175.2016.1202764}}</ref> | '''Gabapentin''' (also known as '''Neurontin''') is a [[psychoactive class::depressant]] substance of the [[chemical class::gabapentinoid]] class. It is a structural analog of the [[neurotransmitter]] [[GABA]] and acts by inhibiting certain calcium channels in the brain, namely α2δ subunit-containing voltage-dependent calcium channels (VGCCs).<ref name="CalandreRico-Villademoros2016">{{cite journal|last1=Calandre|first1=Elena P.|last2=Rico-Villademoros|first2=Fernando|last3=Slim|first3=Mahmoud|title=Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use|journal=Expert Review of Neurotherapeutics|volume=16|issue=11|year=2016|pages=1263–1277|issn=1473-7175|doi=10.1080/14737175.2016.1202764}}</ref> | ||
Gabapentin was originally developed to treat epilepsy and is currently FDA approved to treat postherpetic neuralgia in adults and as an adjunctive therapy in the treatment of partial onset seizures. It is often prescribed off-label for [[restless leg syndrome]], social anxiety disorder, panic disorder, and generalized anxiety disorder.<ref>{{cite book | vauthors=((Schatzberg, A. F.)), ((Cole, J. O.)), ((DeBattista, C.)) | date= 2010 | title=Manual of Clinical Psychopharmacology | publisher=American Psychiatric Pub. | isbn=9781585623778}}</ref><ref>{{cite book | vauthors=((Sobel, S. V.)) | date=5 November 2012 | title=Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission | publisher=W. W. Norton & Company | isbn=9780393708578}}</ref><ref>{{cite book | vauthors=((Richards, D.)), ((Aronson, J.)), ((Coleman, J.)), ((Reynolds, D. J.)) | date=10 November 2011 | title=Oxford Handbook of Practical Drug Therapy | publisher=OUP Oxford | isbn=9780199562855}}</ref> | Gabapentin was originally developed to treat epilepsy and is currently FDA approved to treat postherpetic neuralgia in adults and as an adjunctive therapy in the treatment of partial onset seizures. It is often prescribed off-label for [[restless leg syndrome]], social anxiety disorder, panic disorder, and generalized anxiety disorder.<ref>{{cite book | vauthors=((Schatzberg, A. F.)), ((Cole, J. O.)), ((DeBattista, C.)) | date= 2010 | title=Manual of Clinical Psychopharmacology | publisher=American Psychiatric Pub. | isbn=9781585623778}}</ref><ref>{{cite book | vauthors=((Sobel, S. V.)) | date=5 November 2012 | title=Successful Psychopharmacology: Evidence-Based Treatment Solutions for Achieving Remission | publisher=W. W. Norton & Company | isbn=9780393708578}}</ref><ref>{{cite book | vauthors=((Richards, D.)), ((Aronson, J.)), ((Coleman, J.)), ((Reynolds, D. J.)) | date=10 November 2011 | title=Oxford Handbook of Practical Drug Therapy | publisher=OUP Oxford | isbn=9780199562855}}</ref> | ||